Korean Association for the Study of Intestinal Diseases guidance for clinical practice of adult inflammatory bowel disease during the coronavirus disease 2019 pandemic: expert consensus statements
- Author:
Yong Eun PARK
1
;
Yoo Jin LEE
;
Ji Young CHANG
;
Hyun Joo SONG
;
Duk Hwan KIM
;
Young Joo YANG
;
Byung Chang KIM
;
Jae Gon LEE
;
Hee Chan YANG
;
Miyoung CHOI
;
Seong-Eun KIM
;
Seung-Jae MYUNG
Author Information
- Publication Type:Statement
- From:Intestinal Research 2022;20(4):431-444
- CountryRepublic of Korea
- Language:English
- Abstract: Many unexpected problems have resulted from the unprecedented coronavirus disease 2019 (COVID-19) pandemic. The optimal management of patients with inflammatory bowel disease (IBD) during the COVID-19 pandemic has also been a challenge. Therefore, the Korean Association for the Study of Intestinal Diseases (KASID) developed a consensus statement of experts regarding the management of IBD during the COVID-19 pandemic. This consensus statement made recommendations regarding the risk and treatment of COVID-19 in IBD patients. This statement emphasizes that IBD is not a risk factor for COVID-19, and care should be taken not to exacerbate IBD in patients in remission state by maintaining their medications, except for corticosteroids.
